Trial intelligence / Profile preview

Short-course radiotherapy plus preoperative CAPOX versus standard chemoradiotherapy for high-risk primary rectal cancer

NL-OMON24092Active, not recruiting

Sponsor
University Medical Center Groningen
Start
Jun 2011
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
Countries
1
01

Overview

Trial of capecitabine and oxaliplatin, sponsored by University Medical Center Groningen. Started Jun 2011; status: active, not recruiting.

02

Drugs

capecitabineoxaliplatin

Beyond the preview

Go deeper on NL-OMON24092.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NL-OMON24092.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call